Impel NeuroPharma is a pharmaceutical company that develops and commercializes therapies for patients suffering from central nervous system diseases. Its technology targets the vascular-rich upper nasal cavity and provides rapid absorption, consistent drug biodistribution. The company specializes in the treatment of such diseases as migraine, autism spectrum disorder, and Parkinson's disease.
|HQ||Seattle, WA, US||Map|
Net income (Q2, 2021)
EBIT (Q2, 2021)
Market capitalization (14-Sept-2021)
Closing stock price (14-Sept-2021)
Impel NeuroPharma has 314 Twitter Followers. The number of followers has increased 10.8% month over month and increased 18.2% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Impel NeuroPharma founded?
Impel NeuroPharma was founded in 2008.
Who are Impel NeuroPharma key executives?
Impel NeuroPharma's key executives are John Hoekman, Adrian Adams and John Leaman.
How many employees does Impel NeuroPharma have?
Impel NeuroPharma has 67 employees.
Who are Impel NeuroPharma competitors?
Competitors of Impel NeuroPharma include Aerin Medical, Wuhan Orient Honest Medical and ReBio Technologies.
Where is Impel NeuroPharma headquarters?
Impel NeuroPharma headquarters is located at Waterfront Research Center, 201 Elliott Ave W #260, Seattle.
Where are Impel NeuroPharma offices?
Impel NeuroPharma has an office in Seattle.
How many offices does Impel NeuroPharma have?
Impel NeuroPharma has 1 office.
Receive alerts for 300+ data fields across thousands of companies